Supplementary Table 1. Disease control rates (DCR) recorded (partial response or stable disease) according to RECIST during second-line Molecular Targeted Therapy (MTT).

Patient Characteristics (n=34)		DCR in Everolimus group	DCR in Sunitinib group	P-value
		8/12	17/22	0.687
Gender	Male	5/8	10/14	0.883
	Female	3/4	7/8	0.687
Age mean (SD)		59 (18)	61 (15)	0.787
Inheritance	Sporadic	6/10	15/20	0.768
	Familial (MEN1)	2/2	2/2	-
Primary Tumour Site	Pancreas	7/10	13/17	0.782
	Small Intestinal	1/2	1/2	0.999
	Lung/Thymus	-	2/2	-
	Unknown Primary	.	1/1	-
Liver Tumour Load	No liver metastases	-	1/1	-
	<5 unilobar liver metastases	1/1	6/7	0.999
	5-10 unilobar liver metastases and/or bilobar liver metastases	1/1	-	-
	>10 liver metastases or diffuse liver metastases	6/10	10/14	0.811
Ki67 Group	G1 (ki67 <3%)	1/2	2/2	0.329
	G2 (ki67 3-20%)	7/10	13/15	0.508
	G3 (ki67 >20%)			
Secretory status	Yes	2/3	5/7	0.788
	No	6/9	12/15	0.766
Prior Surgery	Yes	7/10	10/12	0.506
	No	1/2	7/10	0.598
SRS or Ga68-PET	Positive	7/10	14/19	-
	Negative	1/1	--	0.862
	Unknown	0/1	3/3	-
FDG-PET				0.400
	FDG-PET positive	1/1	1/1	0.999
	FDG-PET negative	0/3	1/3	0.643
	Unknown	7/8	13/18	
Previous treatment	SSA or naive	4/6	13/14	0.673
	Pre-treated with chemotherapy	3/6	6/8	-
Charlson Comorbidity Index	0	5/9	15/17	0.332
	1	3/3	2/4	0.350
	2	-	1/1	-
	3	-	-	-

DCR: Disease Control Rate; MTT: Molecular Targeted Therapy; SD: Standard Deviation; SRS: somatostatin receptor scintigraphy; Ga: Gallium; FDG-PET: fluoro-deoxyglucose positron emission tomography

Pearson chi-square test and Fisher's exact test as well as student's t-test were conducted as appropriate.